Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?

462
32
Favorite

Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?

Motley Fool2022-02-05

January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

462

Report

Comment（32）

4153476f
·2022-02-09
Awesome
Reply
Like
Report
andrew123
·2022-02-06
Like
Reply
1
Report
jhlam80
·2022-02-05
Good sharing
Reply
2
Report
SSVC
·2022-02-05
Hmm
Reply
1
Report
RangersXI
·2022-02-05
Ok
Reply
2
Report
luckymonster
·2022-02-05
Like pls. TQ!
Reply
4
Report
ashk3
·2022-02-05
A good reminder to myself
Reply
2
Report
LawrenceLBC
·2022-02-05
Thanks for sharing.
Reply
2
Report
JLSE
·2022-02-05
🤔🤔🤔
Reply
3
Report
moliya
·2022-02-05
I don't care the other two than netflix
Reply
4
Report
Whateverqw
·2022-02-05
Yes?
Reply
3
Report
Turbobo
·2022-02-05
Ok
Reply
3
Report
ND80
·2022-02-05
K
Reply
4
Report
Kundos
·2022-02-05
Ok
Reply
3
Report
tiguru
·2022-02-05
K
Reply
5
Report
JesseC
·2022-02-05
Nice!
Reply
4
Report
RoaringTiger
·2022-02-05
Things are not so clear cut on the surface. Must do your own analysis
Reply
Like
Report
CS2
·2022-02-05
Ok
Reply
3
Report
Kaden0204
·2022-02-05
Buy
Reply
4
Report
Bubble5728
·2022-02-05
Buy
Reply
4
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2208501310?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-02-05 07:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2208501310","market":"us","top_or_hot":-1,"title":"Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?","media":"Motley Fool","content":"<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4550","symbol_name":"红杉资本持仓","start_time":0,"source_url":"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/","article_id":"2208501310","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2208501310","pubTimestamp":1644018270,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Two of the three tickers in question are tempting in that they were once among the market's most beloved names.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4550":"红杉资本持仓","NFLX":"奈飞","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","SPY":"标普500ETF","MRNA":"Moderna, Inc.","BK4504":"桥水持仓","EPAM":"Epam Systems"},"translate_title":"是时候买入标准普尔500一月份表现最差的3只股票了吗？","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPY":1,"EPAM":0.9,"MRNA":0.9,"NFLX":0.9},"content_text":"January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were Netflix (NASDAQ:NFLX), EPAM Systems (NYSE:EPAM), and Moderna (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.MRNA data by YChartsMany discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?Before plowing into any of these stocks -- or any of the S&P 500's other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn't inherently mean it's ripe for a rapid recovery.The sell-offs make some senseTake Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House's effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including Boeing and Starbucks, were canceling their mandate policies.Simply put, the world's losing interest in continuing to fight a coronavirus contagion that's already raced out of control.Image source: Getty Images.Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix's biggest and best competition surfaced right before and during the rise of the coronavirus contagion.The specifics: Walt Disney's Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia's HBO Max launched in May of 2020. Discovery made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. ViacomCBS ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.This isn't to suggest Netflix is doomed. It's still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.Heed the market's warningJust because a stock's been a poor performer of late doesn't mean it's destined to forever go lower due to demand issues, of course.Take the aforementioned software company EPAM Systems, for instance. The stock's crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn't changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.Of the S&P 500's three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There's always more to the story, and more often than not, the market's selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.In simpler terms, big losses don't inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9096810965,"gmtCreate":1644360443785,"gmtModify":1676533915641,"author":{"id":"4107126244872750","authorId":"4107126244872750","name":"4153476f","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4107126244872750","authorIdStr":"4107126244872750"},"htmlText":"Awesome","listText":"Awesome","text":"Awesome","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096810965","repostId":2208501310,"repostType":4,"repost":{"id":"2208501310","kind":"highlight","pubTimestamp":1644018270,"share":"https://ttm.financial/m/news/2208501310?lang=&edition=fundamental","pubTime":"2022-02-05 07:44","market":"us","language":"en","title":"Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2208501310","media":"Motley Fool","summary":"Two of the three tickers in question are tempting in that they were once among the market's most beloved names.","content":"<html><head></head><body><p>January was a tough one for investors, with the <b>S&amp;P 500</b> (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.</p><p>Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were <b>Netflix</b> (NASDAQ:NFLX), <b>EPAM Systems</b> (NYSE:EPAM), and<b> Moderna</b> (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18e27fbd52a0474ccd72c75bb60af5db\" tg-width=\"720\" tg-height=\"483\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>Many discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?</p><p>Before plowing into any of these stocks -- or any of the S&amp;P 500&#39;s other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn&#39;t inherently mean it&#39;s ripe for a rapid recovery.</p><h2>The sell-offs make some sense</h2><p>Take Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.</p><p>Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House&#39;s effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including <b>Boeing</b> and <b>Starbucks</b>, were canceling their mandate policies.</p><p>Simply put, the world&#39;s losing interest in continuing to fight a coronavirus contagion that&#39;s already raced out of control.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1149d759f046abd160561d3662127108\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix&#39;s biggest and best competition surfaced right before and during the rise of the coronavirus contagion.</p><p>The specifics: <b>Walt Disney</b>&#39;s Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia&#39;s HBO Max launched in May of 2020. <b>Discovery</b> made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. <b>ViacomCBS</b> ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.</p><p>This isn&#39;t to suggest Netflix is doomed. It&#39;s still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.</p><h2>Heed the market&#39;s warning</h2><p>Just because a stock&#39;s been a poor performer of late doesn&#39;t mean it&#39;s destined to forever go lower due to demand issues, of course.</p><p>Take the aforementioned software company EPAM Systems, for instance. The stock&#39;s crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn&#39;t changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.</p><p>Of the S&amp;P 500&#39;s three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.</p><p>The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There&#39;s always more to the story, and more often than not, the market&#39;s selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.</p><p>In simpler terms, big losses don&#39;t inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","SPY":"标普500ETF","BK4504":"桥水持仓","BK4550":"红杉资本持仓","NFLX":"奈飞","MRNA":"Moderna, Inc.","EPAM":"Epam Systems"},"source_url":"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208501310","content_text":"January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were Netflix (NASDAQ:NFLX), EPAM Systems (NYSE:EPAM), and Moderna (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.MRNA data by YChartsMany discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?Before plowing into any of these stocks -- or any of the S&P 500's other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn't inherently mean it's ripe for a rapid recovery.The sell-offs make some senseTake Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House's effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including Boeing and Starbucks, were canceling their mandate policies.Simply put, the world's losing interest in continuing to fight a coronavirus contagion that's already raced out of control.Image source: Getty Images.Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix's biggest and best competition surfaced right before and during the rise of the coronavirus contagion.The specifics: Walt Disney's Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia's HBO Max launched in May of 2020. Discovery made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. ViacomCBS ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.This isn't to suggest Netflix is doomed. It's still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.Heed the market's warningJust because a stock's been a poor performer of late doesn't mean it's destined to forever go lower due to demand issues, of course.Take the aforementioned software company EPAM Systems, for instance. The stock's crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn't changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.Of the S&P 500's three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There's always more to the story, and more often than not, the market's selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.In simpler terms, big losses don't inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098865913,"gmtCreate":1644099651175,"gmtModify":1676533888959,"author":{"id":"3576260758860416","authorId":"3576260758860416","name":"andrew123","avatar":"https://community-static.tradeup.com/news/f2a1eaba26272212d42018e60e78b422","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":5,"crmLevelSwitch":0,"idStr":"3576260758860416","authorIdStr":"3576260758860416"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098865913","repostId":2208501310,"repostType":4,"repost":{"id":"2208501310","kind":"highlight","pubTimestamp":1644018270,"share":"https://ttm.financial/m/news/2208501310?lang=&edition=fundamental","pubTime":"2022-02-05 07:44","market":"us","language":"en","title":"Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2208501310","media":"Motley Fool","summary":"Two of the three tickers in question are tempting in that they were once among the market's most beloved names.","content":"<html><head></head><body><p>January was a tough one for investors, with the <b>S&amp;P 500</b> (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.</p><p>Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were <b>Netflix</b> (NASDAQ:NFLX), <b>EPAM Systems</b> (NYSE:EPAM), and<b> Moderna</b> (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18e27fbd52a0474ccd72c75bb60af5db\" tg-width=\"720\" tg-height=\"483\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>Many discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?</p><p>Before plowing into any of these stocks -- or any of the S&amp;P 500&#39;s other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn&#39;t inherently mean it&#39;s ripe for a rapid recovery.</p><h2>The sell-offs make some sense</h2><p>Take Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.</p><p>Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House&#39;s effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including <b>Boeing</b> and <b>Starbucks</b>, were canceling their mandate policies.</p><p>Simply put, the world&#39;s losing interest in continuing to fight a coronavirus contagion that&#39;s already raced out of control.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1149d759f046abd160561d3662127108\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix&#39;s biggest and best competition surfaced right before and during the rise of the coronavirus contagion.</p><p>The specifics: <b>Walt Disney</b>&#39;s Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia&#39;s HBO Max launched in May of 2020. <b>Discovery</b> made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. <b>ViacomCBS</b> ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.</p><p>This isn&#39;t to suggest Netflix is doomed. It&#39;s still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.</p><h2>Heed the market&#39;s warning</h2><p>Just because a stock&#39;s been a poor performer of late doesn&#39;t mean it&#39;s destined to forever go lower due to demand issues, of course.</p><p>Take the aforementioned software company EPAM Systems, for instance. The stock&#39;s crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn&#39;t changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.</p><p>Of the S&amp;P 500&#39;s three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.</p><p>The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There&#39;s always more to the story, and more often than not, the market&#39;s selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.</p><p>In simpler terms, big losses don&#39;t inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","SPY":"标普500ETF","BK4504":"桥水持仓","BK4550":"红杉资本持仓","NFLX":"奈飞","MRNA":"Moderna, Inc.","EPAM":"Epam Systems"},"source_url":"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208501310","content_text":"January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were Netflix (NASDAQ:NFLX), EPAM Systems (NYSE:EPAM), and Moderna (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.MRNA data by YChartsMany discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?Before plowing into any of these stocks -- or any of the S&P 500's other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn't inherently mean it's ripe for a rapid recovery.The sell-offs make some senseTake Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House's effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including Boeing and Starbucks, were canceling their mandate policies.Simply put, the world's losing interest in continuing to fight a coronavirus contagion that's already raced out of control.Image source: Getty Images.Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix's biggest and best competition surfaced right before and during the rise of the coronavirus contagion.The specifics: Walt Disney's Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia's HBO Max launched in May of 2020. Discovery made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. ViacomCBS ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.This isn't to suggest Netflix is doomed. It's still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.Heed the market's warningJust because a stock's been a poor performer of late doesn't mean it's destined to forever go lower due to demand issues, of course.Take the aforementioned software company EPAM Systems, for instance. The stock's crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn't changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.Of the S&P 500's three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There's always more to the story, and more often than not, the market's selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.In simpler terms, big losses don't inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098167066,"gmtCreate":1644049659473,"gmtModify":1676533886414,"author":{"id":"3585055954596184","authorId":"3585055954596184","name":"jhlam80","avatar":"https://static.tigerbbs.com/5a41fd1b8e9a410211181544f9f8e68f","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3585055954596184","authorIdStr":"3585055954596184"},"htmlText":"Good sharing","listText":"Good sharing","text":"Good sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098167066","repostId":2208501310,"repostType":4,"repost":{"id":"2208501310","kind":"highlight","pubTimestamp":1644018270,"share":"https://ttm.financial/m/news/2208501310?lang=&edition=fundamental","pubTime":"2022-02-05 07:44","market":"us","language":"en","title":"Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2208501310","media":"Motley Fool","summary":"Two of the three tickers in question are tempting in that they were once among the market's most beloved names.","content":"<html><head></head><body><p>January was a tough one for investors, with the <b>S&amp;P 500</b> (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.</p><p>Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were <b>Netflix</b> (NASDAQ:NFLX), <b>EPAM Systems</b> (NYSE:EPAM), and<b> Moderna</b> (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18e27fbd52a0474ccd72c75bb60af5db\" tg-width=\"720\" tg-height=\"483\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>Many discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?</p><p>Before plowing into any of these stocks -- or any of the S&amp;P 500&#39;s other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn&#39;t inherently mean it&#39;s ripe for a rapid recovery.</p><h2>The sell-offs make some sense</h2><p>Take Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.</p><p>Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House&#39;s effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including <b>Boeing</b> and <b>Starbucks</b>, were canceling their mandate policies.</p><p>Simply put, the world&#39;s losing interest in continuing to fight a coronavirus contagion that&#39;s already raced out of control.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1149d759f046abd160561d3662127108\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix&#39;s biggest and best competition surfaced right before and during the rise of the coronavirus contagion.</p><p>The specifics: <b>Walt Disney</b>&#39;s Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia&#39;s HBO Max launched in May of 2020. <b>Discovery</b> made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. <b>ViacomCBS</b> ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.</p><p>This isn&#39;t to suggest Netflix is doomed. It&#39;s still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.</p><h2>Heed the market&#39;s warning</h2><p>Just because a stock&#39;s been a poor performer of late doesn&#39;t mean it&#39;s destined to forever go lower due to demand issues, of course.</p><p>Take the aforementioned software company EPAM Systems, for instance. The stock&#39;s crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn&#39;t changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.</p><p>Of the S&amp;P 500&#39;s three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.</p><p>The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There&#39;s always more to the story, and more often than not, the market&#39;s selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.</p><p>In simpler terms, big losses don&#39;t inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","SPY":"标普500ETF","BK4504":"桥水持仓","BK4550":"红杉资本持仓","NFLX":"奈飞","MRNA":"Moderna, Inc.","EPAM":"Epam Systems"},"source_url":"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208501310","content_text":"January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were Netflix (NASDAQ:NFLX), EPAM Systems (NYSE:EPAM), and Moderna (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.MRNA data by YChartsMany discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?Before plowing into any of these stocks -- or any of the S&P 500's other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn't inherently mean it's ripe for a rapid recovery.The sell-offs make some senseTake Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House's effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including Boeing and Starbucks, were canceling their mandate policies.Simply put, the world's losing interest in continuing to fight a coronavirus contagion that's already raced out of control.Image source: Getty Images.Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix's biggest and best competition surfaced right before and during the rise of the coronavirus contagion.The specifics: Walt Disney's Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia's HBO Max launched in May of 2020. Discovery made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. ViacomCBS ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.This isn't to suggest Netflix is doomed. It's still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.Heed the market's warningJust because a stock's been a poor performer of late doesn't mean it's destined to forever go lower due to demand issues, of course.Take the aforementioned software company EPAM Systems, for instance. The stock's crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn't changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.Of the S&P 500's three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There's always more to the story, and more often than not, the market's selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.In simpler terms, big losses don't inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098100602,"gmtCreate":1644033986852,"gmtModify":1676533884743,"author":{"id":"3574906731000207","authorId":"3574906731000207","name":"SSVC","avatar":"https://static.tigerbbs.com/545a5ea462ff4ac7cc100bd3d8d97f72","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574906731000207","authorIdStr":"3574906731000207"},"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098100602","repostId":2208501310,"repostType":4,"repost":{"id":"2208501310","kind":"highlight","pubTimestamp":1644018270,"share":"https://ttm.financial/m/news/2208501310?lang=&edition=fundamental","pubTime":"2022-02-05 07:44","market":"us","language":"en","title":"Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2208501310","media":"Motley Fool","summary":"Two of the three tickers in question are tempting in that they were once among the market's most beloved names.","content":"<html><head></head><body><p>January was a tough one for investors, with the <b>S&amp;P 500</b> (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.</p><p>Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were <b>Netflix</b> (NASDAQ:NFLX), <b>EPAM Systems</b> (NYSE:EPAM), and<b> Moderna</b> (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18e27fbd52a0474ccd72c75bb60af5db\" tg-width=\"720\" tg-height=\"483\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>Many discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?</p><p>Before plowing into any of these stocks -- or any of the S&amp;P 500&#39;s other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn&#39;t inherently mean it&#39;s ripe for a rapid recovery.</p><h2>The sell-offs make some sense</h2><p>Take Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.</p><p>Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House&#39;s effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including <b>Boeing</b> and <b>Starbucks</b>, were canceling their mandate policies.</p><p>Simply put, the world&#39;s losing interest in continuing to fight a coronavirus contagion that&#39;s already raced out of control.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1149d759f046abd160561d3662127108\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix&#39;s biggest and best competition surfaced right before and during the rise of the coronavirus contagion.</p><p>The specifics: <b>Walt Disney</b>&#39;s Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia&#39;s HBO Max launched in May of 2020. <b>Discovery</b> made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. <b>ViacomCBS</b> ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.</p><p>This isn&#39;t to suggest Netflix is doomed. It&#39;s still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.</p><h2>Heed the market&#39;s warning</h2><p>Just because a stock&#39;s been a poor performer of late doesn&#39;t mean it&#39;s destined to forever go lower due to demand issues, of course.</p><p>Take the aforementioned software company EPAM Systems, for instance. The stock&#39;s crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn&#39;t changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.</p><p>Of the S&amp;P 500&#39;s three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.</p><p>The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There&#39;s always more to the story, and more often than not, the market&#39;s selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.</p><p>In simpler terms, big losses don&#39;t inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","SPY":"标普500ETF","BK4504":"桥水持仓","BK4550":"红杉资本持仓","NFLX":"奈飞","MRNA":"Moderna, Inc.","EPAM":"Epam Systems"},"source_url":"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208501310","content_text":"January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were Netflix (NASDAQ:NFLX), EPAM Systems (NYSE:EPAM), and Moderna (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.MRNA data by YChartsMany discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?Before plowing into any of these stocks -- or any of the S&P 500's other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn't inherently mean it's ripe for a rapid recovery.The sell-offs make some senseTake Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House's effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including Boeing and Starbucks, were canceling their mandate policies.Simply put, the world's losing interest in continuing to fight a coronavirus contagion that's already raced out of control.Image source: Getty Images.Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix's biggest and best competition surfaced right before and during the rise of the coronavirus contagion.The specifics: Walt Disney's Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia's HBO Max launched in May of 2020. Discovery made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. ViacomCBS ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.This isn't to suggest Netflix is doomed. It's still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.Heed the market's warningJust because a stock's been a poor performer of late doesn't mean it's destined to forever go lower due to demand issues, of course.Take the aforementioned software company EPAM Systems, for instance. The stock's crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn't changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.Of the S&P 500's three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There's always more to the story, and more often than not, the market's selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.In simpler terms, big losses don't inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098366273,"gmtCreate":1644026915602,"gmtModify":1676533883464,"author":{"id":"3554944369758697","authorId":"3554944369758697","name":"RangersXI","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3554944369758697","authorIdStr":"3554944369758697"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098366273","repostId":2208501310,"repostType":4,"repost":{"id":"2208501310","kind":"highlight","pubTimestamp":1644018270,"share":"https://ttm.financial/m/news/2208501310?lang=&edition=fundamental","pubTime":"2022-02-05 07:44","market":"us","language":"en","title":"Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2208501310","media":"Motley Fool","summary":"Two of the three tickers in question are tempting in that they were once among the market's most beloved names.","content":"<html><head></head><body><p>January was a tough one for investors, with the <b>S&amp;P 500</b> (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.</p><p>Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were <b>Netflix</b> (NASDAQ:NFLX), <b>EPAM Systems</b> (NYSE:EPAM), and<b> Moderna</b> (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18e27fbd52a0474ccd72c75bb60af5db\" tg-width=\"720\" tg-height=\"483\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>Many discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?</p><p>Before plowing into any of these stocks -- or any of the S&amp;P 500&#39;s other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn&#39;t inherently mean it&#39;s ripe for a rapid recovery.</p><h2>The sell-offs make some sense</h2><p>Take Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.</p><p>Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House&#39;s effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including <b>Boeing</b> and <b>Starbucks</b>, were canceling their mandate policies.</p><p>Simply put, the world&#39;s losing interest in continuing to fight a coronavirus contagion that&#39;s already raced out of control.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1149d759f046abd160561d3662127108\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix&#39;s biggest and best competition surfaced right before and during the rise of the coronavirus contagion.</p><p>The specifics: <b>Walt Disney</b>&#39;s Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia&#39;s HBO Max launched in May of 2020. <b>Discovery</b> made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. <b>ViacomCBS</b> ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.</p><p>This isn&#39;t to suggest Netflix is doomed. It&#39;s still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.</p><h2>Heed the market&#39;s warning</h2><p>Just because a stock&#39;s been a poor performer of late doesn&#39;t mean it&#39;s destined to forever go lower due to demand issues, of course.</p><p>Take the aforementioned software company EPAM Systems, for instance. The stock&#39;s crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn&#39;t changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.</p><p>Of the S&amp;P 500&#39;s three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.</p><p>The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There&#39;s always more to the story, and more often than not, the market&#39;s selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.</p><p>In simpler terms, big losses don&#39;t inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","SPY":"标普500ETF","BK4504":"桥水持仓","BK4550":"红杉资本持仓","NFLX":"奈飞","MRNA":"Moderna, Inc.","EPAM":"Epam Systems"},"source_url":"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208501310","content_text":"January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were Netflix (NASDAQ:NFLX), EPAM Systems (NYSE:EPAM), and Moderna (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.MRNA data by YChartsMany discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?Before plowing into any of these stocks -- or any of the S&P 500's other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn't inherently mean it's ripe for a rapid recovery.The sell-offs make some senseTake Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House's effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including Boeing and Starbucks, were canceling their mandate policies.Simply put, the world's losing interest in continuing to fight a coronavirus contagion that's already raced out of control.Image source: Getty Images.Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix's biggest and best competition surfaced right before and during the rise of the coronavirus contagion.The specifics: Walt Disney's Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia's HBO Max launched in May of 2020. Discovery made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. ViacomCBS ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.This isn't to suggest Netflix is doomed. It's still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.Heed the market's warningJust because a stock's been a poor performer of late doesn't mean it's destined to forever go lower due to demand issues, of course.Take the aforementioned software company EPAM Systems, for instance. The stock's crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn't changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.Of the S&P 500's three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There's always more to the story, and more often than not, the market's selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.In simpler terms, big losses don't inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098385534,"gmtCreate":1644025754754,"gmtModify":1676533883257,"author":{"id":"4106315466683200","authorId":"4106315466683200","name":"luckymonster","avatar":"https://static.itradeup.com/news/cea754f2931a4b71b8f86b693ef3d961","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4106315466683200","authorIdStr":"4106315466683200"},"htmlText":"Like pls. TQ!","listText":"Like pls. TQ!","text":"Like pls. TQ!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098385534","repostId":2208501310,"repostType":4,"repost":{"id":"2208501310","kind":"highlight","pubTimestamp":1644018270,"share":"https://ttm.financial/m/news/2208501310?lang=&edition=fundamental","pubTime":"2022-02-05 07:44","market":"us","language":"en","title":"Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2208501310","media":"Motley Fool","summary":"Two of the three tickers in question are tempting in that they were once among the market's most beloved names.","content":"<html><head></head><body><p>January was a tough one for investors, with the <b>S&amp;P 500</b> (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.</p><p>Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were <b>Netflix</b> (NASDAQ:NFLX), <b>EPAM Systems</b> (NYSE:EPAM), and<b> Moderna</b> (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18e27fbd52a0474ccd72c75bb60af5db\" tg-width=\"720\" tg-height=\"483\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>Many discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?</p><p>Before plowing into any of these stocks -- or any of the S&amp;P 500&#39;s other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn&#39;t inherently mean it&#39;s ripe for a rapid recovery.</p><h2>The sell-offs make some sense</h2><p>Take Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.</p><p>Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House&#39;s effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including <b>Boeing</b> and <b>Starbucks</b>, were canceling their mandate policies.</p><p>Simply put, the world&#39;s losing interest in continuing to fight a coronavirus contagion that&#39;s already raced out of control.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1149d759f046abd160561d3662127108\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix&#39;s biggest and best competition surfaced right before and during the rise of the coronavirus contagion.</p><p>The specifics: <b>Walt Disney</b>&#39;s Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia&#39;s HBO Max launched in May of 2020. <b>Discovery</b> made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. <b>ViacomCBS</b> ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.</p><p>This isn&#39;t to suggest Netflix is doomed. It&#39;s still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.</p><h2>Heed the market&#39;s warning</h2><p>Just because a stock&#39;s been a poor performer of late doesn&#39;t mean it&#39;s destined to forever go lower due to demand issues, of course.</p><p>Take the aforementioned software company EPAM Systems, for instance. The stock&#39;s crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn&#39;t changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.</p><p>Of the S&amp;P 500&#39;s three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.</p><p>The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There&#39;s always more to the story, and more often than not, the market&#39;s selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.</p><p>In simpler terms, big losses don&#39;t inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","SPY":"标普500ETF","BK4504":"桥水持仓","BK4550":"红杉资本持仓","NFLX":"奈飞","MRNA":"Moderna, Inc.","EPAM":"Epam Systems"},"source_url":"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208501310","content_text":"January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were Netflix (NASDAQ:NFLX), EPAM Systems (NYSE:EPAM), and Moderna (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.MRNA data by YChartsMany discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?Before plowing into any of these stocks -- or any of the S&P 500's other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn't inherently mean it's ripe for a rapid recovery.The sell-offs make some senseTake Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House's effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including Boeing and Starbucks, were canceling their mandate policies.Simply put, the world's losing interest in continuing to fight a coronavirus contagion that's already raced out of control.Image source: Getty Images.Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix's biggest and best competition surfaced right before and during the rise of the coronavirus contagion.The specifics: Walt Disney's Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia's HBO Max launched in May of 2020. Discovery made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. ViacomCBS ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.This isn't to suggest Netflix is doomed. It's still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.Heed the market's warningJust because a stock's been a poor performer of late doesn't mean it's destined to forever go lower due to demand issues, of course.Take the aforementioned software company EPAM Systems, for instance. The stock's crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn't changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.Of the S&P 500's three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There's always more to the story, and more often than not, the market's selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.In simpler terms, big losses don't inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098382158,"gmtCreate":1644025634726,"gmtModify":1676533882980,"author":{"id":"3568528830578074","authorId":"3568528830578074","name":"ashk3","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3568528830578074","authorIdStr":"3568528830578074"},"htmlText":"A good reminder to myself&nbsp;","listText":"A good reminder to myself&nbsp;","text":"A good reminder to myself","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098382158","repostId":2208501310,"repostType":4,"repost":{"id":"2208501310","kind":"highlight","pubTimestamp":1644018270,"share":"https://ttm.financial/m/news/2208501310?lang=&edition=fundamental","pubTime":"2022-02-05 07:44","market":"us","language":"en","title":"Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2208501310","media":"Motley Fool","summary":"Two of the three tickers in question are tempting in that they were once among the market's most beloved names.","content":"<html><head></head><body><p>January was a tough one for investors, with the <b>S&amp;P 500</b> (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.</p><p>Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were <b>Netflix</b> (NASDAQ:NFLX), <b>EPAM Systems</b> (NYSE:EPAM), and<b> Moderna</b> (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18e27fbd52a0474ccd72c75bb60af5db\" tg-width=\"720\" tg-height=\"483\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>Many discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?</p><p>Before plowing into any of these stocks -- or any of the S&amp;P 500&#39;s other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn&#39;t inherently mean it&#39;s ripe for a rapid recovery.</p><h2>The sell-offs make some sense</h2><p>Take Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.</p><p>Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House&#39;s effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including <b>Boeing</b> and <b>Starbucks</b>, were canceling their mandate policies.</p><p>Simply put, the world&#39;s losing interest in continuing to fight a coronavirus contagion that&#39;s already raced out of control.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1149d759f046abd160561d3662127108\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix&#39;s biggest and best competition surfaced right before and during the rise of the coronavirus contagion.</p><p>The specifics: <b>Walt Disney</b>&#39;s Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia&#39;s HBO Max launched in May of 2020. <b>Discovery</b> made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. <b>ViacomCBS</b> ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.</p><p>This isn&#39;t to suggest Netflix is doomed. It&#39;s still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.</p><h2>Heed the market&#39;s warning</h2><p>Just because a stock&#39;s been a poor performer of late doesn&#39;t mean it&#39;s destined to forever go lower due to demand issues, of course.</p><p>Take the aforementioned software company EPAM Systems, for instance. The stock&#39;s crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn&#39;t changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.</p><p>Of the S&amp;P 500&#39;s three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.</p><p>The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There&#39;s always more to the story, and more often than not, the market&#39;s selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.</p><p>In simpler terms, big losses don&#39;t inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","SPY":"标普500ETF","BK4504":"桥水持仓","BK4550":"红杉资本持仓","NFLX":"奈飞","MRNA":"Moderna, Inc.","EPAM":"Epam Systems"},"source_url":"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208501310","content_text":"January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were Netflix (NASDAQ:NFLX), EPAM Systems (NYSE:EPAM), and Moderna (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.MRNA data by YChartsMany discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?Before plowing into any of these stocks -- or any of the S&P 500's other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn't inherently mean it's ripe for a rapid recovery.The sell-offs make some senseTake Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House's effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including Boeing and Starbucks, were canceling their mandate policies.Simply put, the world's losing interest in continuing to fight a coronavirus contagion that's already raced out of control.Image source: Getty Images.Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix's biggest and best competition surfaced right before and during the rise of the coronavirus contagion.The specifics: Walt Disney's Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia's HBO Max launched in May of 2020. Discovery made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. ViacomCBS ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.This isn't to suggest Netflix is doomed. It's still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.Heed the market's warningJust because a stock's been a poor performer of late doesn't mean it's destined to forever go lower due to demand issues, of course.Take the aforementioned software company EPAM Systems, for instance. The stock's crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn't changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.Of the S&P 500's three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There's always more to the story, and more often than not, the market's selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.In simpler terms, big losses don't inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098388035,"gmtCreate":1644025333018,"gmtModify":1676533882960,"author":{"id":"4099538117833270","authorId":"4099538117833270","name":"LawrenceLBC","avatar":"https://static.tigerbbs.com/d77996f17116a3bc466fc0271bc81357","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"4099538117833270","authorIdStr":"4099538117833270"},"htmlText":"Thanks for sharing.","listText":"Thanks for sharing.","text":"Thanks for sharing.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098388035","repostId":2208501310,"repostType":4,"repost":{"id":"2208501310","kind":"highlight","pubTimestamp":1644018270,"share":"https://ttm.financial/m/news/2208501310?lang=&edition=fundamental","pubTime":"2022-02-05 07:44","market":"us","language":"en","title":"Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2208501310","media":"Motley Fool","summary":"Two of the three tickers in question are tempting in that they were once among the market's most beloved names.","content":"<html><head></head><body><p>January was a tough one for investors, with the <b>S&amp;P 500</b> (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.</p><p>Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were <b>Netflix</b> (NASDAQ:NFLX), <b>EPAM Systems</b> (NYSE:EPAM), and<b> Moderna</b> (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18e27fbd52a0474ccd72c75bb60af5db\" tg-width=\"720\" tg-height=\"483\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>Many discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?</p><p>Before plowing into any of these stocks -- or any of the S&amp;P 500&#39;s other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn&#39;t inherently mean it&#39;s ripe for a rapid recovery.</p><h2>The sell-offs make some sense</h2><p>Take Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.</p><p>Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House&#39;s effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including <b>Boeing</b> and <b>Starbucks</b>, were canceling their mandate policies.</p><p>Simply put, the world&#39;s losing interest in continuing to fight a coronavirus contagion that&#39;s already raced out of control.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1149d759f046abd160561d3662127108\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix&#39;s biggest and best competition surfaced right before and during the rise of the coronavirus contagion.</p><p>The specifics: <b>Walt Disney</b>&#39;s Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia&#39;s HBO Max launched in May of 2020. <b>Discovery</b> made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. <b>ViacomCBS</b> ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.</p><p>This isn&#39;t to suggest Netflix is doomed. It&#39;s still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.</p><h2>Heed the market&#39;s warning</h2><p>Just because a stock&#39;s been a poor performer of late doesn&#39;t mean it&#39;s destined to forever go lower due to demand issues, of course.</p><p>Take the aforementioned software company EPAM Systems, for instance. The stock&#39;s crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn&#39;t changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.</p><p>Of the S&amp;P 500&#39;s three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.</p><p>The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There&#39;s always more to the story, and more often than not, the market&#39;s selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.</p><p>In simpler terms, big losses don&#39;t inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","SPY":"标普500ETF","BK4504":"桥水持仓","BK4550":"红杉资本持仓","NFLX":"奈飞","MRNA":"Moderna, Inc.","EPAM":"Epam Systems"},"source_url":"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208501310","content_text":"January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were Netflix (NASDAQ:NFLX), EPAM Systems (NYSE:EPAM), and Moderna (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.MRNA data by YChartsMany discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?Before plowing into any of these stocks -- or any of the S&P 500's other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn't inherently mean it's ripe for a rapid recovery.The sell-offs make some senseTake Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House's effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including Boeing and Starbucks, were canceling their mandate policies.Simply put, the world's losing interest in continuing to fight a coronavirus contagion that's already raced out of control.Image source: Getty Images.Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix's biggest and best competition surfaced right before and during the rise of the coronavirus contagion.The specifics: Walt Disney's Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia's HBO Max launched in May of 2020. Discovery made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. ViacomCBS ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.This isn't to suggest Netflix is doomed. It's still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.Heed the market's warningJust because a stock's been a poor performer of late doesn't mean it's destined to forever go lower due to demand issues, of course.Take the aforementioned software company EPAM Systems, for instance. The stock's crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn't changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.Of the S&P 500's three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There's always more to the story, and more often than not, the market's selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.In simpler terms, big losses don't inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098389661,"gmtCreate":1644025085502,"gmtModify":1676533882922,"author":{"id":"4089028522442560","authorId":"4089028522442560","name":"JLSE","avatar":"https://static.tigerbbs.com/b2e0c693d513ad9276d36f34b54134c2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4089028522442560","authorIdStr":"4089028522442560"},"htmlText":"🤔🤔🤔","listText":"🤔🤔🤔","text":"🤔🤔🤔","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098389661","repostId":2208501310,"repostType":4,"repost":{"id":"2208501310","kind":"highlight","pubTimestamp":1644018270,"share":"https://ttm.financial/m/news/2208501310?lang=&edition=fundamental","pubTime":"2022-02-05 07:44","market":"us","language":"en","title":"Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2208501310","media":"Motley Fool","summary":"Two of the three tickers in question are tempting in that they were once among the market's most beloved names.","content":"<html><head></head><body><p>January was a tough one for investors, with the <b>S&amp;P 500</b> (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.</p><p>Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were <b>Netflix</b> (NASDAQ:NFLX), <b>EPAM Systems</b> (NYSE:EPAM), and<b> Moderna</b> (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18e27fbd52a0474ccd72c75bb60af5db\" tg-width=\"720\" tg-height=\"483\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>Many discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?</p><p>Before plowing into any of these stocks -- or any of the S&amp;P 500&#39;s other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn&#39;t inherently mean it&#39;s ripe for a rapid recovery.</p><h2>The sell-offs make some sense</h2><p>Take Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.</p><p>Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House&#39;s effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including <b>Boeing</b> and <b>Starbucks</b>, were canceling their mandate policies.</p><p>Simply put, the world&#39;s losing interest in continuing to fight a coronavirus contagion that&#39;s already raced out of control.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1149d759f046abd160561d3662127108\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix&#39;s biggest and best competition surfaced right before and during the rise of the coronavirus contagion.</p><p>The specifics: <b>Walt Disney</b>&#39;s Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia&#39;s HBO Max launched in May of 2020. <b>Discovery</b> made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. <b>ViacomCBS</b> ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.</p><p>This isn&#39;t to suggest Netflix is doomed. It&#39;s still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.</p><h2>Heed the market&#39;s warning</h2><p>Just because a stock&#39;s been a poor performer of late doesn&#39;t mean it&#39;s destined to forever go lower due to demand issues, of course.</p><p>Take the aforementioned software company EPAM Systems, for instance. The stock&#39;s crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn&#39;t changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.</p><p>Of the S&amp;P 500&#39;s three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.</p><p>The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There&#39;s always more to the story, and more often than not, the market&#39;s selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.</p><p>In simpler terms, big losses don&#39;t inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","SPY":"标普500ETF","BK4504":"桥水持仓","BK4550":"红杉资本持仓","NFLX":"奈飞","MRNA":"Moderna, Inc.","EPAM":"Epam Systems"},"source_url":"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208501310","content_text":"January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were Netflix (NASDAQ:NFLX), EPAM Systems (NYSE:EPAM), and Moderna (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.MRNA data by YChartsMany discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?Before plowing into any of these stocks -- or any of the S&P 500's other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn't inherently mean it's ripe for a rapid recovery.The sell-offs make some senseTake Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House's effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including Boeing and Starbucks, were canceling their mandate policies.Simply put, the world's losing interest in continuing to fight a coronavirus contagion that's already raced out of control.Image source: Getty Images.Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix's biggest and best competition surfaced right before and during the rise of the coronavirus contagion.The specifics: Walt Disney's Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia's HBO Max launched in May of 2020. Discovery made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. ViacomCBS ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.This isn't to suggest Netflix is doomed. It's still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.Heed the market's warningJust because a stock's been a poor performer of late doesn't mean it's destined to forever go lower due to demand issues, of course.Take the aforementioned software company EPAM Systems, for instance. The stock's crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn't changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.Of the S&P 500's three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There's always more to the story, and more often than not, the market's selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.In simpler terms, big losses don't inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098380508,"gmtCreate":1644024950152,"gmtModify":1676533882853,"author":{"id":"3552850525395609","authorId":"3552850525395609","name":"moliya","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/7b75ce0c34afff716602792a5d0929dd","crmLevel":5,"crmLevelSwitch":1,"idStr":"3552850525395609","authorIdStr":"3552850525395609"},"htmlText":"I don't care the other two than netflix","listText":"I don't care the other two than netflix","text":"I don't care the other two than netflix","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098380508","repostId":2208501310,"repostType":4,"repost":{"id":"2208501310","kind":"highlight","pubTimestamp":1644018270,"share":"https://ttm.financial/m/news/2208501310?lang=&edition=fundamental","pubTime":"2022-02-05 07:44","market":"us","language":"en","title":"Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2208501310","media":"Motley Fool","summary":"Two of the three tickers in question are tempting in that they were once among the market's most beloved names.","content":"<html><head></head><body><p>January was a tough one for investors, with the <b>S&amp;P 500</b> (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.</p><p>Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were <b>Netflix</b> (NASDAQ:NFLX), <b>EPAM Systems</b> (NYSE:EPAM), and<b> Moderna</b> (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18e27fbd52a0474ccd72c75bb60af5db\" tg-width=\"720\" tg-height=\"483\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>Many discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?</p><p>Before plowing into any of these stocks -- or any of the S&amp;P 500&#39;s other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn&#39;t inherently mean it&#39;s ripe for a rapid recovery.</p><h2>The sell-offs make some sense</h2><p>Take Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.</p><p>Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House&#39;s effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including <b>Boeing</b> and <b>Starbucks</b>, were canceling their mandate policies.</p><p>Simply put, the world&#39;s losing interest in continuing to fight a coronavirus contagion that&#39;s already raced out of control.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1149d759f046abd160561d3662127108\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix&#39;s biggest and best competition surfaced right before and during the rise of the coronavirus contagion.</p><p>The specifics: <b>Walt Disney</b>&#39;s Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia&#39;s HBO Max launched in May of 2020. <b>Discovery</b> made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. <b>ViacomCBS</b> ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.</p><p>This isn&#39;t to suggest Netflix is doomed. It&#39;s still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.</p><h2>Heed the market&#39;s warning</h2><p>Just because a stock&#39;s been a poor performer of late doesn&#39;t mean it&#39;s destined to forever go lower due to demand issues, of course.</p><p>Take the aforementioned software company EPAM Systems, for instance. The stock&#39;s crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn&#39;t changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.</p><p>Of the S&amp;P 500&#39;s three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.</p><p>The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There&#39;s always more to the story, and more often than not, the market&#39;s selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.</p><p>In simpler terms, big losses don&#39;t inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","SPY":"标普500ETF","BK4504":"桥水持仓","BK4550":"红杉资本持仓","NFLX":"奈飞","MRNA":"Moderna, Inc.","EPAM":"Epam Systems"},"source_url":"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208501310","content_text":"January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were Netflix (NASDAQ:NFLX), EPAM Systems (NYSE:EPAM), and Moderna (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.MRNA data by YChartsMany discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?Before plowing into any of these stocks -- or any of the S&P 500's other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn't inherently mean it's ripe for a rapid recovery.The sell-offs make some senseTake Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House's effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including Boeing and Starbucks, were canceling their mandate policies.Simply put, the world's losing interest in continuing to fight a coronavirus contagion that's already raced out of control.Image source: Getty Images.Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix's biggest and best competition surfaced right before and during the rise of the coronavirus contagion.The specifics: Walt Disney's Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia's HBO Max launched in May of 2020. Discovery made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. ViacomCBS ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.This isn't to suggest Netflix is doomed. It's still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.Heed the market's warningJust because a stock's been a poor performer of late doesn't mean it's destined to forever go lower due to demand issues, of course.Take the aforementioned software company EPAM Systems, for instance. The stock's crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn't changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.Of the S&P 500's three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There's always more to the story, and more often than not, the market's selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.In simpler terms, big losses don't inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098380396,"gmtCreate":1644024857534,"gmtModify":1676533882844,"author":{"id":"3582029110525423","authorId":"3582029110525423","name":"Whateverqw","avatar":"https://static.tigerbbs.com/7b82b69926257ee0d05417f42b935ac0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582029110525423","authorIdStr":"3582029110525423"},"htmlText":"Yes?","listText":"Yes?","text":"Yes?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098380396","repostId":2208501310,"repostType":4,"repost":{"id":"2208501310","kind":"highlight","pubTimestamp":1644018270,"share":"https://ttm.financial/m/news/2208501310?lang=&edition=fundamental","pubTime":"2022-02-05 07:44","market":"us","language":"en","title":"Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2208501310","media":"Motley Fool","summary":"Two of the three tickers in question are tempting in that they were once among the market's most beloved names.","content":"<html><head></head><body><p>January was a tough one for investors, with the <b>S&amp;P 500</b> (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.</p><p>Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were <b>Netflix</b> (NASDAQ:NFLX), <b>EPAM Systems</b> (NYSE:EPAM), and<b> Moderna</b> (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18e27fbd52a0474ccd72c75bb60af5db\" tg-width=\"720\" tg-height=\"483\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>Many discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?</p><p>Before plowing into any of these stocks -- or any of the S&amp;P 500&#39;s other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn&#39;t inherently mean it&#39;s ripe for a rapid recovery.</p><h2>The sell-offs make some sense</h2><p>Take Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.</p><p>Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House&#39;s effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including <b>Boeing</b> and <b>Starbucks</b>, were canceling their mandate policies.</p><p>Simply put, the world&#39;s losing interest in continuing to fight a coronavirus contagion that&#39;s already raced out of control.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1149d759f046abd160561d3662127108\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix&#39;s biggest and best competition surfaced right before and during the rise of the coronavirus contagion.</p><p>The specifics: <b>Walt Disney</b>&#39;s Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia&#39;s HBO Max launched in May of 2020. <b>Discovery</b> made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. <b>ViacomCBS</b> ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.</p><p>This isn&#39;t to suggest Netflix is doomed. It&#39;s still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.</p><h2>Heed the market&#39;s warning</h2><p>Just because a stock&#39;s been a poor performer of late doesn&#39;t mean it&#39;s destined to forever go lower due to demand issues, of course.</p><p>Take the aforementioned software company EPAM Systems, for instance. The stock&#39;s crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn&#39;t changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.</p><p>Of the S&amp;P 500&#39;s three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.</p><p>The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There&#39;s always more to the story, and more often than not, the market&#39;s selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.</p><p>In simpler terms, big losses don&#39;t inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","SPY":"标普500ETF","BK4504":"桥水持仓","BK4550":"红杉资本持仓","NFLX":"奈飞","MRNA":"Moderna, Inc.","EPAM":"Epam Systems"},"source_url":"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208501310","content_text":"January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were Netflix (NASDAQ:NFLX), EPAM Systems (NYSE:EPAM), and Moderna (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.MRNA data by YChartsMany discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?Before plowing into any of these stocks -- or any of the S&P 500's other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn't inherently mean it's ripe for a rapid recovery.The sell-offs make some senseTake Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House's effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including Boeing and Starbucks, were canceling their mandate policies.Simply put, the world's losing interest in continuing to fight a coronavirus contagion that's already raced out of control.Image source: Getty Images.Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix's biggest and best competition surfaced right before and during the rise of the coronavirus contagion.The specifics: Walt Disney's Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia's HBO Max launched in May of 2020. Discovery made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. ViacomCBS ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.This isn't to suggest Netflix is doomed. It's still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.Heed the market's warningJust because a stock's been a poor performer of late doesn't mean it's destined to forever go lower due to demand issues, of course.Take the aforementioned software company EPAM Systems, for instance. The stock's crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn't changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.Of the S&P 500's three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There's always more to the story, and more often than not, the market's selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.In simpler terms, big losses don't inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098317556,"gmtCreate":1644024811663,"gmtModify":1676533882836,"author":{"id":"4090202748844200","authorId":"4090202748844200","name":"Turbobo","avatar":"https://static.tigerbbs.com/fbfb7690052b45745da7270aa672c42d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4090202748844200","authorIdStr":"4090202748844200"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098317556","repostId":2208501310,"repostType":4,"repost":{"id":"2208501310","kind":"highlight","pubTimestamp":1644018270,"share":"https://ttm.financial/m/news/2208501310?lang=&edition=fundamental","pubTime":"2022-02-05 07:44","market":"us","language":"en","title":"Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2208501310","media":"Motley Fool","summary":"Two of the three tickers in question are tempting in that they were once among the market's most beloved names.","content":"<html><head></head><body><p>January was a tough one for investors, with the <b>S&amp;P 500</b> (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.</p><p>Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were <b>Netflix</b> (NASDAQ:NFLX), <b>EPAM Systems</b> (NYSE:EPAM), and<b> Moderna</b> (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18e27fbd52a0474ccd72c75bb60af5db\" tg-width=\"720\" tg-height=\"483\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>Many discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?</p><p>Before plowing into any of these stocks -- or any of the S&amp;P 500&#39;s other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn&#39;t inherently mean it&#39;s ripe for a rapid recovery.</p><h2>The sell-offs make some sense</h2><p>Take Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.</p><p>Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House&#39;s effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including <b>Boeing</b> and <b>Starbucks</b>, were canceling their mandate policies.</p><p>Simply put, the world&#39;s losing interest in continuing to fight a coronavirus contagion that&#39;s already raced out of control.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1149d759f046abd160561d3662127108\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix&#39;s biggest and best competition surfaced right before and during the rise of the coronavirus contagion.</p><p>The specifics: <b>Walt Disney</b>&#39;s Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia&#39;s HBO Max launched in May of 2020. <b>Discovery</b> made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. <b>ViacomCBS</b> ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.</p><p>This isn&#39;t to suggest Netflix is doomed. It&#39;s still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.</p><h2>Heed the market&#39;s warning</h2><p>Just because a stock&#39;s been a poor performer of late doesn&#39;t mean it&#39;s destined to forever go lower due to demand issues, of course.</p><p>Take the aforementioned software company EPAM Systems, for instance. The stock&#39;s crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn&#39;t changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.</p><p>Of the S&amp;P 500&#39;s three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.</p><p>The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There&#39;s always more to the story, and more often than not, the market&#39;s selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.</p><p>In simpler terms, big losses don&#39;t inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","SPY":"标普500ETF","BK4504":"桥水持仓","BK4550":"红杉资本持仓","NFLX":"奈飞","MRNA":"Moderna, Inc.","EPAM":"Epam Systems"},"source_url":"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208501310","content_text":"January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were Netflix (NASDAQ:NFLX), EPAM Systems (NYSE:EPAM), and Moderna (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.MRNA data by YChartsMany discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?Before plowing into any of these stocks -- or any of the S&P 500's other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn't inherently mean it's ripe for a rapid recovery.The sell-offs make some senseTake Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House's effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including Boeing and Starbucks, were canceling their mandate policies.Simply put, the world's losing interest in continuing to fight a coronavirus contagion that's already raced out of control.Image source: Getty Images.Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix's biggest and best competition surfaced right before and during the rise of the coronavirus contagion.The specifics: Walt Disney's Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia's HBO Max launched in May of 2020. Discovery made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. ViacomCBS ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.This isn't to suggest Netflix is doomed. It's still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.Heed the market's warningJust because a stock's been a poor performer of late doesn't mean it's destined to forever go lower due to demand issues, of course.Take the aforementioned software company EPAM Systems, for instance. The stock's crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn't changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.Of the S&P 500's three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There's always more to the story, and more often than not, the market's selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.In simpler terms, big losses don't inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098317249,"gmtCreate":1644024791184,"gmtModify":1676533882836,"author":{"id":"3558608283589593","authorId":"3558608283589593","name":"ND80","avatar":"https://community-static.tradeup.com/news/bb0f12b9cd568049d5ef4fd8cc522646","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3558608283589593","authorIdStr":"3558608283589593"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098317249","repostId":2208501310,"repostType":4,"repost":{"id":"2208501310","kind":"highlight","pubTimestamp":1644018270,"share":"https://ttm.financial/m/news/2208501310?lang=&edition=fundamental","pubTime":"2022-02-05 07:44","market":"us","language":"en","title":"Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2208501310","media":"Motley Fool","summary":"Two of the three tickers in question are tempting in that they were once among the market's most beloved names.","content":"<html><head></head><body><p>January was a tough one for investors, with the <b>S&amp;P 500</b> (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.</p><p>Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were <b>Netflix</b> (NASDAQ:NFLX), <b>EPAM Systems</b> (NYSE:EPAM), and<b> Moderna</b> (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18e27fbd52a0474ccd72c75bb60af5db\" tg-width=\"720\" tg-height=\"483\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>Many discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?</p><p>Before plowing into any of these stocks -- or any of the S&amp;P 500&#39;s other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn&#39;t inherently mean it&#39;s ripe for a rapid recovery.</p><h2>The sell-offs make some sense</h2><p>Take Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.</p><p>Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House&#39;s effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including <b>Boeing</b> and <b>Starbucks</b>, were canceling their mandate policies.</p><p>Simply put, the world&#39;s losing interest in continuing to fight a coronavirus contagion that&#39;s already raced out of control.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1149d759f046abd160561d3662127108\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix&#39;s biggest and best competition surfaced right before and during the rise of the coronavirus contagion.</p><p>The specifics: <b>Walt Disney</b>&#39;s Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia&#39;s HBO Max launched in May of 2020. <b>Discovery</b> made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. <b>ViacomCBS</b> ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.</p><p>This isn&#39;t to suggest Netflix is doomed. It&#39;s still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.</p><h2>Heed the market&#39;s warning</h2><p>Just because a stock&#39;s been a poor performer of late doesn&#39;t mean it&#39;s destined to forever go lower due to demand issues, of course.</p><p>Take the aforementioned software company EPAM Systems, for instance. The stock&#39;s crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn&#39;t changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.</p><p>Of the S&amp;P 500&#39;s three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.</p><p>The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There&#39;s always more to the story, and more often than not, the market&#39;s selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.</p><p>In simpler terms, big losses don&#39;t inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","SPY":"标普500ETF","BK4504":"桥水持仓","BK4550":"红杉资本持仓","NFLX":"奈飞","MRNA":"Moderna, Inc.","EPAM":"Epam Systems"},"source_url":"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208501310","content_text":"January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were Netflix (NASDAQ:NFLX), EPAM Systems (NYSE:EPAM), and Moderna (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.MRNA data by YChartsMany discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?Before plowing into any of these stocks -- or any of the S&P 500's other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn't inherently mean it's ripe for a rapid recovery.The sell-offs make some senseTake Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House's effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including Boeing and Starbucks, were canceling their mandate policies.Simply put, the world's losing interest in continuing to fight a coronavirus contagion that's already raced out of control.Image source: Getty Images.Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix's biggest and best competition surfaced right before and during the rise of the coronavirus contagion.The specifics: Walt Disney's Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia's HBO Max launched in May of 2020. Discovery made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. ViacomCBS ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.This isn't to suggest Netflix is doomed. It's still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.Heed the market's warningJust because a stock's been a poor performer of late doesn't mean it's destined to forever go lower due to demand issues, of course.Take the aforementioned software company EPAM Systems, for instance. The stock's crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn't changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.Of the S&P 500's three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There's always more to the story, and more often than not, the market's selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.In simpler terms, big losses don't inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098314409,"gmtCreate":1644024698208,"gmtModify":1676533882804,"author":{"id":"4093470092873140","authorId":"4093470092873140","name":"Kundos","avatar":"https://community-static.tradeup.com/news/ce1a3c71cbcd8d00d16dfeac879fe818","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4093470092873140","authorIdStr":"4093470092873140"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098314409","repostId":2208501310,"repostType":4,"repost":{"id":"2208501310","kind":"highlight","pubTimestamp":1644018270,"share":"https://ttm.financial/m/news/2208501310?lang=&edition=fundamental","pubTime":"2022-02-05 07:44","market":"us","language":"en","title":"Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2208501310","media":"Motley Fool","summary":"Two of the three tickers in question are tempting in that they were once among the market's most beloved names.","content":"<html><head></head><body><p>January was a tough one for investors, with the <b>S&amp;P 500</b> (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.</p><p>Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were <b>Netflix</b> (NASDAQ:NFLX), <b>EPAM Systems</b> (NYSE:EPAM), and<b> Moderna</b> (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18e27fbd52a0474ccd72c75bb60af5db\" tg-width=\"720\" tg-height=\"483\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>Many discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?</p><p>Before plowing into any of these stocks -- or any of the S&amp;P 500&#39;s other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn&#39;t inherently mean it&#39;s ripe for a rapid recovery.</p><h2>The sell-offs make some sense</h2><p>Take Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.</p><p>Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House&#39;s effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including <b>Boeing</b> and <b>Starbucks</b>, were canceling their mandate policies.</p><p>Simply put, the world&#39;s losing interest in continuing to fight a coronavirus contagion that&#39;s already raced out of control.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1149d759f046abd160561d3662127108\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix&#39;s biggest and best competition surfaced right before and during the rise of the coronavirus contagion.</p><p>The specifics: <b>Walt Disney</b>&#39;s Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia&#39;s HBO Max launched in May of 2020. <b>Discovery</b> made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. <b>ViacomCBS</b> ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.</p><p>This isn&#39;t to suggest Netflix is doomed. It&#39;s still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.</p><h2>Heed the market&#39;s warning</h2><p>Just because a stock&#39;s been a poor performer of late doesn&#39;t mean it&#39;s destined to forever go lower due to demand issues, of course.</p><p>Take the aforementioned software company EPAM Systems, for instance. The stock&#39;s crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn&#39;t changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.</p><p>Of the S&amp;P 500&#39;s three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.</p><p>The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There&#39;s always more to the story, and more often than not, the market&#39;s selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.</p><p>In simpler terms, big losses don&#39;t inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","SPY":"标普500ETF","BK4504":"桥水持仓","BK4550":"红杉资本持仓","NFLX":"奈飞","MRNA":"Moderna, Inc.","EPAM":"Epam Systems"},"source_url":"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208501310","content_text":"January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were Netflix (NASDAQ:NFLX), EPAM Systems (NYSE:EPAM), and Moderna (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.MRNA data by YChartsMany discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?Before plowing into any of these stocks -- or any of the S&P 500's other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn't inherently mean it's ripe for a rapid recovery.The sell-offs make some senseTake Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House's effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including Boeing and Starbucks, were canceling their mandate policies.Simply put, the world's losing interest in continuing to fight a coronavirus contagion that's already raced out of control.Image source: Getty Images.Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix's biggest and best competition surfaced right before and during the rise of the coronavirus contagion.The specifics: Walt Disney's Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia's HBO Max launched in May of 2020. Discovery made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. ViacomCBS ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.This isn't to suggest Netflix is doomed. It's still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.Heed the market's warningJust because a stock's been a poor performer of late doesn't mean it's destined to forever go lower due to demand issues, of course.Take the aforementioned software company EPAM Systems, for instance. The stock's crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn't changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.Of the S&P 500's three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There's always more to the story, and more often than not, the market's selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.In simpler terms, big losses don't inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098314951,"gmtCreate":1644024642704,"gmtModify":1676533882786,"author":{"id":"3581713302392824","authorId":"3581713302392824","name":"tiguru","avatar":"https://static.tigerbbs.com/95800411cd10450bf31ccbab2743ae25","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581713302392824","authorIdStr":"3581713302392824"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098314951","repostId":2208501310,"repostType":4,"repost":{"id":"2208501310","kind":"highlight","pubTimestamp":1644018270,"share":"https://ttm.financial/m/news/2208501310?lang=&edition=fundamental","pubTime":"2022-02-05 07:44","market":"us","language":"en","title":"Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2208501310","media":"Motley Fool","summary":"Two of the three tickers in question are tempting in that they were once among the market's most beloved names.","content":"<html><head></head><body><p>January was a tough one for investors, with the <b>S&amp;P 500</b> (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.</p><p>Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were <b>Netflix</b> (NASDAQ:NFLX), <b>EPAM Systems</b> (NYSE:EPAM), and<b> Moderna</b> (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18e27fbd52a0474ccd72c75bb60af5db\" tg-width=\"720\" tg-height=\"483\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>Many discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?</p><p>Before plowing into any of these stocks -- or any of the S&amp;P 500&#39;s other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn&#39;t inherently mean it&#39;s ripe for a rapid recovery.</p><h2>The sell-offs make some sense</h2><p>Take Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.</p><p>Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House&#39;s effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including <b>Boeing</b> and <b>Starbucks</b>, were canceling their mandate policies.</p><p>Simply put, the world&#39;s losing interest in continuing to fight a coronavirus contagion that&#39;s already raced out of control.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1149d759f046abd160561d3662127108\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix&#39;s biggest and best competition surfaced right before and during the rise of the coronavirus contagion.</p><p>The specifics: <b>Walt Disney</b>&#39;s Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia&#39;s HBO Max launched in May of 2020. <b>Discovery</b> made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. <b>ViacomCBS</b> ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.</p><p>This isn&#39;t to suggest Netflix is doomed. It&#39;s still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.</p><h2>Heed the market&#39;s warning</h2><p>Just because a stock&#39;s been a poor performer of late doesn&#39;t mean it&#39;s destined to forever go lower due to demand issues, of course.</p><p>Take the aforementioned software company EPAM Systems, for instance. The stock&#39;s crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn&#39;t changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.</p><p>Of the S&amp;P 500&#39;s three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.</p><p>The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There&#39;s always more to the story, and more often than not, the market&#39;s selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.</p><p>In simpler terms, big losses don&#39;t inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","SPY":"标普500ETF","BK4504":"桥水持仓","BK4550":"红杉资本持仓","NFLX":"奈飞","MRNA":"Moderna, Inc.","EPAM":"Epam Systems"},"source_url":"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208501310","content_text":"January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were Netflix (NASDAQ:NFLX), EPAM Systems (NYSE:EPAM), and Moderna (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.MRNA data by YChartsMany discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?Before plowing into any of these stocks -- or any of the S&P 500's other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn't inherently mean it's ripe for a rapid recovery.The sell-offs make some senseTake Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House's effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including Boeing and Starbucks, were canceling their mandate policies.Simply put, the world's losing interest in continuing to fight a coronavirus contagion that's already raced out of control.Image source: Getty Images.Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix's biggest and best competition surfaced right before and during the rise of the coronavirus contagion.The specifics: Walt Disney's Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia's HBO Max launched in May of 2020. Discovery made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. ViacomCBS ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.This isn't to suggest Netflix is doomed. It's still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.Heed the market's warningJust because a stock's been a poor performer of late doesn't mean it's destined to forever go lower due to demand issues, of course.Take the aforementioned software company EPAM Systems, for instance. The stock's crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn't changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.Of the S&P 500's three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There's always more to the story, and more often than not, the market's selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.In simpler terms, big losses don't inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098312252,"gmtCreate":1644024494893,"gmtModify":1676533882754,"author":{"id":"3570851668487502","authorId":"3570851668487502","name":"JesseC","avatar":"https://community-static.tradeup.com/news/aa75283eff8e6ec8f384f30a9ae50e16","vip":1,"crmLevel":4,"crmLevelSwitch":1,"idStr":"3570851668487502","authorIdStr":"3570851668487502"},"htmlText":"Nice!","listText":"Nice!","text":"Nice!","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098312252","repostId":2208501310,"repostType":4,"repost":{"id":"2208501310","kind":"highlight","pubTimestamp":1644018270,"share":"https://ttm.financial/m/news/2208501310?lang=&edition=fundamental","pubTime":"2022-02-05 07:44","market":"us","language":"en","title":"Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2208501310","media":"Motley Fool","summary":"Two of the three tickers in question are tempting in that they were once among the market's most beloved names.","content":"<html><head></head><body><p>January was a tough one for investors, with the <b>S&amp;P 500</b> (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.</p><p>Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were <b>Netflix</b> (NASDAQ:NFLX), <b>EPAM Systems</b> (NYSE:EPAM), and<b> Moderna</b> (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18e27fbd52a0474ccd72c75bb60af5db\" tg-width=\"720\" tg-height=\"483\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>Many discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?</p><p>Before plowing into any of these stocks -- or any of the S&amp;P 500&#39;s other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn&#39;t inherently mean it&#39;s ripe for a rapid recovery.</p><h2>The sell-offs make some sense</h2><p>Take Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.</p><p>Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House&#39;s effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including <b>Boeing</b> and <b>Starbucks</b>, were canceling their mandate policies.</p><p>Simply put, the world&#39;s losing interest in continuing to fight a coronavirus contagion that&#39;s already raced out of control.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1149d759f046abd160561d3662127108\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix&#39;s biggest and best competition surfaced right before and during the rise of the coronavirus contagion.</p><p>The specifics: <b>Walt Disney</b>&#39;s Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia&#39;s HBO Max launched in May of 2020. <b>Discovery</b> made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. <b>ViacomCBS</b> ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.</p><p>This isn&#39;t to suggest Netflix is doomed. It&#39;s still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.</p><h2>Heed the market&#39;s warning</h2><p>Just because a stock&#39;s been a poor performer of late doesn&#39;t mean it&#39;s destined to forever go lower due to demand issues, of course.</p><p>Take the aforementioned software company EPAM Systems, for instance. The stock&#39;s crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn&#39;t changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.</p><p>Of the S&amp;P 500&#39;s three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.</p><p>The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There&#39;s always more to the story, and more often than not, the market&#39;s selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.</p><p>In simpler terms, big losses don&#39;t inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","SPY":"标普500ETF","BK4504":"桥水持仓","BK4550":"红杉资本持仓","NFLX":"奈飞","MRNA":"Moderna, Inc.","EPAM":"Epam Systems"},"source_url":"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208501310","content_text":"January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were Netflix (NASDAQ:NFLX), EPAM Systems (NYSE:EPAM), and Moderna (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.MRNA data by YChartsMany discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?Before plowing into any of these stocks -- or any of the S&P 500's other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn't inherently mean it's ripe for a rapid recovery.The sell-offs make some senseTake Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House's effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including Boeing and Starbucks, were canceling their mandate policies.Simply put, the world's losing interest in continuing to fight a coronavirus contagion that's already raced out of control.Image source: Getty Images.Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix's biggest and best competition surfaced right before and during the rise of the coronavirus contagion.The specifics: Walt Disney's Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia's HBO Max launched in May of 2020. Discovery made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. ViacomCBS ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.This isn't to suggest Netflix is doomed. It's still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.Heed the market's warningJust because a stock's been a poor performer of late doesn't mean it's destined to forever go lower due to demand issues, of course.Take the aforementioned software company EPAM Systems, for instance. The stock's crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn't changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.Of the S&P 500's three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There's always more to the story, and more often than not, the market's selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.In simpler terms, big losses don't inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098313855,"gmtCreate":1644024013102,"gmtModify":1676533882655,"author":{"id":"4105443374405760","authorId":"4105443374405760","name":"RoaringTiger","avatar":"https://static.itradeup.com/news/c2aee6e44a0d6a91f2442e004db0e4eb","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0,"idStr":"4105443374405760","authorIdStr":"4105443374405760"},"htmlText":"Things are not so clear cut on the surface. Must do your own analysis","listText":"Things are not so clear cut on the surface. Must do your own analysis","text":"Things are not so clear cut on the surface. Must do your own analysis","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098313855","repostId":2208501310,"repostType":4,"repost":{"id":"2208501310","kind":"highlight","pubTimestamp":1644018270,"share":"https://ttm.financial/m/news/2208501310?lang=&edition=fundamental","pubTime":"2022-02-05 07:44","market":"us","language":"en","title":"Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2208501310","media":"Motley Fool","summary":"Two of the three tickers in question are tempting in that they were once among the market's most beloved names.","content":"<html><head></head><body><p>January was a tough one for investors, with the <b>S&amp;P 500</b> (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.</p><p>Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were <b>Netflix</b> (NASDAQ:NFLX), <b>EPAM Systems</b> (NYSE:EPAM), and<b> Moderna</b> (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18e27fbd52a0474ccd72c75bb60af5db\" tg-width=\"720\" tg-height=\"483\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>Many discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?</p><p>Before plowing into any of these stocks -- or any of the S&amp;P 500&#39;s other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn&#39;t inherently mean it&#39;s ripe for a rapid recovery.</p><h2>The sell-offs make some sense</h2><p>Take Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.</p><p>Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House&#39;s effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including <b>Boeing</b> and <b>Starbucks</b>, were canceling their mandate policies.</p><p>Simply put, the world&#39;s losing interest in continuing to fight a coronavirus contagion that&#39;s already raced out of control.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1149d759f046abd160561d3662127108\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix&#39;s biggest and best competition surfaced right before and during the rise of the coronavirus contagion.</p><p>The specifics: <b>Walt Disney</b>&#39;s Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia&#39;s HBO Max launched in May of 2020. <b>Discovery</b> made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. <b>ViacomCBS</b> ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.</p><p>This isn&#39;t to suggest Netflix is doomed. It&#39;s still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.</p><h2>Heed the market&#39;s warning</h2><p>Just because a stock&#39;s been a poor performer of late doesn&#39;t mean it&#39;s destined to forever go lower due to demand issues, of course.</p><p>Take the aforementioned software company EPAM Systems, for instance. The stock&#39;s crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn&#39;t changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.</p><p>Of the S&amp;P 500&#39;s three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.</p><p>The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There&#39;s always more to the story, and more often than not, the market&#39;s selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.</p><p>In simpler terms, big losses don&#39;t inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","SPY":"标普500ETF","BK4504":"桥水持仓","BK4550":"红杉资本持仓","NFLX":"奈飞","MRNA":"Moderna, Inc.","EPAM":"Epam Systems"},"source_url":"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208501310","content_text":"January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were Netflix (NASDAQ:NFLX), EPAM Systems (NYSE:EPAM), and Moderna (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.MRNA data by YChartsMany discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?Before plowing into any of these stocks -- or any of the S&P 500's other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn't inherently mean it's ripe for a rapid recovery.The sell-offs make some senseTake Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House's effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including Boeing and Starbucks, were canceling their mandate policies.Simply put, the world's losing interest in continuing to fight a coronavirus contagion that's already raced out of control.Image source: Getty Images.Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix's biggest and best competition surfaced right before and during the rise of the coronavirus contagion.The specifics: Walt Disney's Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia's HBO Max launched in May of 2020. Discovery made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. ViacomCBS ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.This isn't to suggest Netflix is doomed. It's still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.Heed the market's warningJust because a stock's been a poor performer of late doesn't mean it's destined to forever go lower due to demand issues, of course.Take the aforementioned software company EPAM Systems, for instance. The stock's crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn't changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.Of the S&P 500's three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There's always more to the story, and more often than not, the market's selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.In simpler terms, big losses don't inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098313128,"gmtCreate":1644023990463,"gmtModify":1676533882648,"author":{"id":"3563688986414344","authorId":"3563688986414344","name":"CS2","avatar":"https://static.tigerbbs.com/615455e55d5ee6d62d6d1fbcbfa4e02a","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":3,"crmLevelSwitch":0,"idStr":"3563688986414344","authorIdStr":"3563688986414344"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098313128","repostId":2208501310,"repostType":4,"repost":{"id":"2208501310","kind":"highlight","pubTimestamp":1644018270,"share":"https://ttm.financial/m/news/2208501310?lang=&edition=fundamental","pubTime":"2022-02-05 07:44","market":"us","language":"en","title":"Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2208501310","media":"Motley Fool","summary":"Two of the three tickers in question are tempting in that they were once among the market's most beloved names.","content":"<html><head></head><body><p>January was a tough one for investors, with the <b>S&amp;P 500</b> (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.</p><p>Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were <b>Netflix</b> (NASDAQ:NFLX), <b>EPAM Systems</b> (NYSE:EPAM), and<b> Moderna</b> (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18e27fbd52a0474ccd72c75bb60af5db\" tg-width=\"720\" tg-height=\"483\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>Many discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?</p><p>Before plowing into any of these stocks -- or any of the S&amp;P 500&#39;s other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn&#39;t inherently mean it&#39;s ripe for a rapid recovery.</p><h2>The sell-offs make some sense</h2><p>Take Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.</p><p>Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House&#39;s effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including <b>Boeing</b> and <b>Starbucks</b>, were canceling their mandate policies.</p><p>Simply put, the world&#39;s losing interest in continuing to fight a coronavirus contagion that&#39;s already raced out of control.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1149d759f046abd160561d3662127108\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix&#39;s biggest and best competition surfaced right before and during the rise of the coronavirus contagion.</p><p>The specifics: <b>Walt Disney</b>&#39;s Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia&#39;s HBO Max launched in May of 2020. <b>Discovery</b> made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. <b>ViacomCBS</b> ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.</p><p>This isn&#39;t to suggest Netflix is doomed. It&#39;s still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.</p><h2>Heed the market&#39;s warning</h2><p>Just because a stock&#39;s been a poor performer of late doesn&#39;t mean it&#39;s destined to forever go lower due to demand issues, of course.</p><p>Take the aforementioned software company EPAM Systems, for instance. The stock&#39;s crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn&#39;t changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.</p><p>Of the S&amp;P 500&#39;s three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.</p><p>The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There&#39;s always more to the story, and more often than not, the market&#39;s selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.</p><p>In simpler terms, big losses don&#39;t inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","SPY":"标普500ETF","BK4504":"桥水持仓","BK4550":"红杉资本持仓","NFLX":"奈飞","MRNA":"Moderna, Inc.","EPAM":"Epam Systems"},"source_url":"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208501310","content_text":"January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were Netflix (NASDAQ:NFLX), EPAM Systems (NYSE:EPAM), and Moderna (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.MRNA data by YChartsMany discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?Before plowing into any of these stocks -- or any of the S&P 500's other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn't inherently mean it's ripe for a rapid recovery.The sell-offs make some senseTake Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House's effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including Boeing and Starbucks, were canceling their mandate policies.Simply put, the world's losing interest in continuing to fight a coronavirus contagion that's already raced out of control.Image source: Getty Images.Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix's biggest and best competition surfaced right before and during the rise of the coronavirus contagion.The specifics: Walt Disney's Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia's HBO Max launched in May of 2020. Discovery made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. ViacomCBS ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.This isn't to suggest Netflix is doomed. It's still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.Heed the market's warningJust because a stock's been a poor performer of late doesn't mean it's destined to forever go lower due to demand issues, of course.Take the aforementioned software company EPAM Systems, for instance. The stock's crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn't changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.Of the S&P 500's three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There's always more to the story, and more often than not, the market's selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.In simpler terms, big losses don't inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098334101,"gmtCreate":1644023495641,"gmtModify":1676533882561,"author":{"id":"4097384260129050","authorId":"4097384260129050","name":"Kaden0204","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"4097384260129050","authorIdStr":"4097384260129050"},"htmlText":"Buy","listText":"Buy","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098334101","repostId":2208501310,"repostType":4,"repost":{"id":"2208501310","kind":"highlight","pubTimestamp":1644018270,"share":"https://ttm.financial/m/news/2208501310?lang=&edition=fundamental","pubTime":"2022-02-05 07:44","market":"us","language":"en","title":"Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2208501310","media":"Motley Fool","summary":"Two of the three tickers in question are tempting in that they were once among the market's most beloved names.","content":"<html><head></head><body><p>January was a tough one for investors, with the <b>S&amp;P 500</b> (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.</p><p>Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were <b>Netflix</b> (NASDAQ:NFLX), <b>EPAM Systems</b> (NYSE:EPAM), and<b> Moderna</b> (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18e27fbd52a0474ccd72c75bb60af5db\" tg-width=\"720\" tg-height=\"483\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>Many discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?</p><p>Before plowing into any of these stocks -- or any of the S&amp;P 500&#39;s other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn&#39;t inherently mean it&#39;s ripe for a rapid recovery.</p><h2>The sell-offs make some sense</h2><p>Take Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.</p><p>Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House&#39;s effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including <b>Boeing</b> and <b>Starbucks</b>, were canceling their mandate policies.</p><p>Simply put, the world&#39;s losing interest in continuing to fight a coronavirus contagion that&#39;s already raced out of control.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1149d759f046abd160561d3662127108\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix&#39;s biggest and best competition surfaced right before and during the rise of the coronavirus contagion.</p><p>The specifics: <b>Walt Disney</b>&#39;s Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia&#39;s HBO Max launched in May of 2020. <b>Discovery</b> made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. <b>ViacomCBS</b> ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.</p><p>This isn&#39;t to suggest Netflix is doomed. It&#39;s still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.</p><h2>Heed the market&#39;s warning</h2><p>Just because a stock&#39;s been a poor performer of late doesn&#39;t mean it&#39;s destined to forever go lower due to demand issues, of course.</p><p>Take the aforementioned software company EPAM Systems, for instance. The stock&#39;s crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn&#39;t changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.</p><p>Of the S&amp;P 500&#39;s three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.</p><p>The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There&#39;s always more to the story, and more often than not, the market&#39;s selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.</p><p>In simpler terms, big losses don&#39;t inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","SPY":"标普500ETF","BK4504":"桥水持仓","BK4550":"红杉资本持仓","NFLX":"奈飞","MRNA":"Moderna, Inc.","EPAM":"Epam Systems"},"source_url":"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208501310","content_text":"January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were Netflix (NASDAQ:NFLX), EPAM Systems (NYSE:EPAM), and Moderna (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.MRNA data by YChartsMany discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?Before plowing into any of these stocks -- or any of the S&P 500's other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn't inherently mean it's ripe for a rapid recovery.The sell-offs make some senseTake Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House's effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including Boeing and Starbucks, were canceling their mandate policies.Simply put, the world's losing interest in continuing to fight a coronavirus contagion that's already raced out of control.Image source: Getty Images.Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix's biggest and best competition surfaced right before and during the rise of the coronavirus contagion.The specifics: Walt Disney's Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia's HBO Max launched in May of 2020. Discovery made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. ViacomCBS ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.This isn't to suggest Netflix is doomed. It's still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.Heed the market's warningJust because a stock's been a poor performer of late doesn't mean it's destined to forever go lower due to demand issues, of course.Take the aforementioned software company EPAM Systems, for instance. The stock's crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn't changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.Of the S&P 500's three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There's always more to the story, and more often than not, the market's selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.In simpler terms, big losses don't inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098338446,"gmtCreate":1644023148956,"gmtModify":1676533882469,"author":{"id":"3575454990112554","authorId":"3575454990112554","name":"Bubble5728","avatar":"https://static.tigerbbs.com/ffe6f8385b6f65785cb6f3337622382d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575454990112554","authorIdStr":"3575454990112554"},"htmlText":"Buy","listText":"Buy","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098338446","repostId":2208501310,"repostType":4,"repost":{"id":"2208501310","kind":"highlight","pubTimestamp":1644018270,"share":"https://ttm.financial/m/news/2208501310?lang=&edition=fundamental","pubTime":"2022-02-05 07:44","market":"us","language":"en","title":"Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2208501310","media":"Motley Fool","summary":"Two of the three tickers in question are tempting in that they were once among the market's most beloved names.","content":"<html><head></head><body><p>January was a tough one for investors, with the <b>S&amp;P 500</b> (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.</p><p>Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were <b>Netflix</b> (NASDAQ:NFLX), <b>EPAM Systems</b> (NYSE:EPAM), and<b> Moderna</b> (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18e27fbd52a0474ccd72c75bb60af5db\" tg-width=\"720\" tg-height=\"483\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>Many discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?</p><p>Before plowing into any of these stocks -- or any of the S&amp;P 500&#39;s other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn&#39;t inherently mean it&#39;s ripe for a rapid recovery.</p><h2>The sell-offs make some sense</h2><p>Take Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.</p><p>Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House&#39;s effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including <b>Boeing</b> and <b>Starbucks</b>, were canceling their mandate policies.</p><p>Simply put, the world&#39;s losing interest in continuing to fight a coronavirus contagion that&#39;s already raced out of control.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1149d759f046abd160561d3662127108\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix&#39;s biggest and best competition surfaced right before and during the rise of the coronavirus contagion.</p><p>The specifics: <b>Walt Disney</b>&#39;s Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia&#39;s HBO Max launched in May of 2020. <b>Discovery</b> made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. <b>ViacomCBS</b> ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.</p><p>This isn&#39;t to suggest Netflix is doomed. It&#39;s still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.</p><h2>Heed the market&#39;s warning</h2><p>Just because a stock&#39;s been a poor performer of late doesn&#39;t mean it&#39;s destined to forever go lower due to demand issues, of course.</p><p>Take the aforementioned software company EPAM Systems, for instance. The stock&#39;s crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn&#39;t changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.</p><p>Of the S&amp;P 500&#39;s three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.</p><p>The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There&#39;s always more to the story, and more often than not, the market&#39;s selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.</p><p>In simpler terms, big losses don&#39;t inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 07:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","SPY":"标普500ETF","BK4504":"桥水持仓","BK4550":"红杉资本持仓","NFLX":"奈飞","MRNA":"Moderna, Inc.","EPAM":"Epam Systems"},"source_url":"https://www.fool.com/investing/2022/02/04/time-buy-sp-500-worst-performing-january-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208501310","content_text":"January was a tough one for investors, with the S&P 500 (SNPINDEX:^GSPC) losing a little more than 5.2% of its value. That sell-off marks the worst month for the market since March of 2020 when stocks plummeted as the COVID-19 pandemic was declared.Many of the stocks that make up the index saw share prices fall much more. The worst of the worst were Netflix (NASDAQ:NFLX), EPAM Systems (NYSE:EPAM), and Moderna (NASDAQ:MRNA). The first two names tumbled 29% last month, while Moderna shares ended January more than 33% lower. The vaccine trade has clearly lost its luster.MRNA data by YChartsMany discount investors are, of course, mulling purchases of these beaten-down names. Why pay full price when you can buy a stock on sale?Before plowing into any of these stocks -- or any of the S&P 500's other big January losers, for that matter -- take a step back and inspect your true motivation. Just because a ticker has lost a massive amount of value in a short period of time doesn't inherently mean it's ripe for a rapid recovery.The sell-offs make some senseTake Moderna as an example. While it was one of the most ballyhooed names in the race to create a COVID-19 vaccine, shares of the drugmaker overstepped their sustainable, justifiable long-term value in 2020 and 2021. With the initially created vaccines not quite as effective as hoped at curbing the spread of the omicron variant -- and even less effective against the new omicron subvariant -- the world is losing interest in what increasingly looks like a never-ending chase for immunity. Denmark and England have essentially dropped all pandemic-related restrictions.Support for vaccine mandates is withering anyway. The U.S. Supreme Court ruled against the White House's effort to force all large companies to impose their own vaccination mandates on employees. Even without that ruling, many companies, including Boeing and Starbucks, were canceling their mandate policies.Simply put, the world's losing interest in continuing to fight a coronavirus contagion that's already raced out of control.Image source: Getty Images.Netflix is in a different but comparable situation. While plenty of supporters and shareholders see the recent subscriber growth lull as a temporary headwind linked to strong growth during the early days of the pandemic, that view overlooks a critical detail. That is, Netflix's biggest and best competition surfaced right before and during the rise of the coronavirus contagion.The specifics: Walt Disney's Disney+ debuted in November of 2019, a month before COVID-19 was first detected in China. WarnerMedia's HBO Max launched in May of 2020. Discovery made Discovery+ available in early 2021, and it is already serving 20 million paying subscribers. ViacomCBS ramped up its streaming efforts in the middle of the pandemic as well. Its Pluto TV platform now serves 54.4 million viewers, doubling its headcount as of early 2020. Its total number of premium streaming subscribers also more than doubled during that period.This isn't to suggest Netflix is doomed. It's still the most compelling brand in the streaming business. The recent streak of disappointing subscriber growth, however, may reflect an increasingly crowded market more than tougher comps. The former is a more permanent challenge.Heed the market's warningJust because a stock's been a poor performer of late doesn't mean it's destined to forever go lower due to demand issues, of course.Take the aforementioned software company EPAM Systems, for instance. The stock's crashed since the end of last year, mostly thanks to an excessive run-up in 2021. The fundamental bullish argument hasn't changed for this growth name, though. Analysts are still calling for 30% sales growth this year, driving comparable earnings growth as a result. Companies still need help moving into the digital world, and EPAM is still well-positioned as the go-to solutions provider.Of the S&P 500's three biggest laggards in January, though, this one is the only one where the sell-off is clearly a mistake.The thing is, this limited number of sharply sold-off stocks that are actually firm buys following their meltdowns is nothing new. There's always more to the story, and more often than not, the market's selling is a reasonable warning that a company is at least worth viewing through a lens of healthy doubt.In simpler terms, big losses don't inherently make a stock a buy, even when that stock is a well-known ticker. Always look at the bigger picture.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":462,"commentSize":32,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}